FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136997> ?p ?o ?g. }

• W4324136997 endingPage "196" @default.
• W4324136997 startingPage "196" @default.
• W4324136997 abstract "196 Background: An aggressive subset of prostate cancers (AVPC) respond poorly to androgen signaling inhibitors, have limited therapeutic options and a dismal prognosis. Preclinical models of AVPC display functional alterations in DNA damage response (DDR) pathways linked to platinum and PARP inhibitor (PARPi) sensitivity. We hypothesized that PARPi (ola) maintenance following CabCarb would improve the progression free survival (PFS) of men with AVPC. We performed a tissue-rich randomized trial for men with AVPC to address this hypothesis and unravel the heterogeneity of AVPC by linking genomic and transcriptomic analyses with clinical outcomes. Methods: In a single-institution study, men with CRPC meeting ≥ 1 of 9 AVPC criteria and ECOG performance status (PS) of 0-2 received 6 cycles of Cab 20-25mg/m 2 and Carbo (AUC 3-4). Men completing 6 cycles without progressive disease (PD) were randomized 2:1 to Ola 300mg BID vs. observation (Obs). The primary endpoint is to estimate PFS in those randomized and we aimed to detect a difference of 3.9 vs. 7.8 months. Subgroup comparisons between patients who had PD prior to randomization (platinum-resistant) vs. those randomized (platinum sensitive) were made with chi-square tests for categorical baseline characteristics, and Kruskal-Wallis test for continuous measures. Results: 96 patients started CabCarb. Their median age was 67 years (43-86), most were white/non-Hispanic (74%), had an ECOG score of 0 (64%), bone metastases (79%), and no prior docetaxel therapy (59%). Of the 96, 7 (7.3%) went off study for reasons unrelated to PD and 36 (37.5%) had PD prior to randomization. Patients with PD prior to randomization were more likely at baseline to have received prior docetaxel (59% vs. 29%; p=0.004), have bone metastases (92% vs. 71%; p=0.03), have lower hemoglobin (11.4 vs. 12. 4; p=0.02), higher LDH (359 vs. 260; p=0.01), lower albumin (4.0 vs. 4.2; p=0.04), and higher AlkPhos (181.5 vs. 98.5; p=0.01) compared to patients who went on to randomization. With a median follow up time of 38.9 months post randomization, the median PFS was 2.3 months (95% confidence interval: 1.3, 4.6 months) for Observation and 4.9 (3.5, 6.3) months with Olaparib (p=0.12). The median OS was 16.2 (6.8, 26.4) for observation and 15.3 (10.2, 28.4) months with Olaparib (p=0.56). Conclusions: These data highlight the heterogeneity within the AVPC subset. Ongoing molecular analyses of sequential liquid and tumor tissue will illuminate the underpinnings of this heterogeneity and identify targets for additional combinatorial strategies. Clinical trial information: NCT03263650 ." @default.
• W4324136997 created "2023-03-15" @default.
• W4324136997 creator A5008820123 @default.
• W4324136997 creator A5021183845 @default.
• W4324136997 creator A5021224140 @default.
• W4324136997 creator A5022629958 @default.
• W4324136997 creator A5026202651 @default.
• W4324136997 creator A5042000405 @default.
• W4324136997 creator A5043747346 @default.
• W4324136997 creator A5045858447 @default.
• W4324136997 creator A5048915309 @default.
• W4324136997 creator A5056289722 @default.
• W4324136997 creator A5059272502 @default.
• W4324136997 creator A5062740919 @default.
• W4324136997 creator A5078910130 @default.
• W4324136997 creator A5080526034 @default.
• W4324136997 date "2023-02-20" @default.
• W4324136997 modified "2023-09-27" @default.
• W4324136997 title "Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC)." @default.
• W4324136997 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.196" @default.
• W4324136997 hasPublicationYear "2023" @default.
• W4324136997 type Work @default.
• W4324136997 citedByCount "0" @default.
• W4324136997 crossrefType "journal-article" @default.
• W4324136997 hasAuthorship W4324136997A5008820123 @default.
• W4324136997 hasAuthorship W4324136997A5021183845 @default.
• W4324136997 hasAuthorship W4324136997A5021224140 @default.
• W4324136997 hasAuthorship W4324136997A5022629958 @default.
• W4324136997 hasAuthorship W4324136997A5026202651 @default.
• W4324136997 hasAuthorship W4324136997A5042000405 @default.
• W4324136997 hasAuthorship W4324136997A5043747346 @default.
• W4324136997 hasAuthorship W4324136997A5045858447 @default.
• W4324136997 hasAuthorship W4324136997A5048915309 @default.
• W4324136997 hasAuthorship W4324136997A5056289722 @default.
• W4324136997 hasAuthorship W4324136997A5059272502 @default.
• W4324136997 hasAuthorship W4324136997A5062740919 @default.
• W4324136997 hasAuthorship W4324136997A5078910130 @default.
• W4324136997 hasAuthorship W4324136997A5080526034 @default.
• W4324136997 hasConcept C104317684 @default.
• W4324136997 hasConcept C121608353 @default.
• W4324136997 hasConcept C126322002 @default.
• W4324136997 hasConcept C143998085 @default.
• W4324136997 hasConcept C168563851 @default.
• W4324136997 hasConcept C182979987 @default.
• W4324136997 hasConcept C185592680 @default.
• W4324136997 hasConcept C203092338 @default.
• W4324136997 hasConcept C2776694085 @default.
• W4324136997 hasConcept C2778239845 @default.
• W4324136997 hasConcept C2779138821 @default.
• W4324136997 hasConcept C2779962180 @default.
• W4324136997 hasConcept C2780192828 @default.
• W4324136997 hasConcept C2781190966 @default.
• W4324136997 hasConcept C2781451048 @default.
• W4324136997 hasConcept C55493867 @default.
• W4324136997 hasConcept C71924100 @default.
• W4324136997 hasConcept C82381507 @default.
• W4324136997 hasConceptScore W4324136997C104317684 @default.
• W4324136997 hasConceptScore W4324136997C121608353 @default.
• W4324136997 hasConceptScore W4324136997C126322002 @default.
• W4324136997 hasConceptScore W4324136997C143998085 @default.
• W4324136997 hasConceptScore W4324136997C168563851 @default.
• W4324136997 hasConceptScore W4324136997C182979987 @default.
• W4324136997 hasConceptScore W4324136997C185592680 @default.
• W4324136997 hasConceptScore W4324136997C203092338 @default.
• W4324136997 hasConceptScore W4324136997C2776694085 @default.
• W4324136997 hasConceptScore W4324136997C2778239845 @default.
• W4324136997 hasConceptScore W4324136997C2779138821 @default.
• W4324136997 hasConceptScore W4324136997C2779962180 @default.
• W4324136997 hasConceptScore W4324136997C2780192828 @default.
• W4324136997 hasConceptScore W4324136997C2781190966 @default.
• W4324136997 hasConceptScore W4324136997C2781451048 @default.
• W4324136997 hasConceptScore W4324136997C55493867 @default.
• W4324136997 hasConceptScore W4324136997C71924100 @default.
• W4324136997 hasConceptScore W4324136997C82381507 @default.
• W4324136997 hasIssue "6_suppl" @default.
• W4324136997 hasLocation W43241369971 @default.
• W4324136997 hasOpenAccess W4324136997 @default.
• W4324136997 hasPrimaryLocation W43241369971 @default.
• W4324136997 hasRelatedWork W2013653877 @default.
• W4324136997 hasRelatedWork W2027569686 @default.
• W4324136997 hasRelatedWork W2299690226 @default.
• W4324136997 hasRelatedWork W2439707001 @default.
• W4324136997 hasRelatedWork W2471989939 @default.
• W4324136997 hasRelatedWork W3132581442 @default.
• W4324136997 hasRelatedWork W3179281685 @default.
• W4324136997 hasRelatedWork W4210360853 @default.
• W4324136997 hasRelatedWork W4297477309 @default.
• W4324136997 hasRelatedWork W4324136997 @default.
• W4324136997 hasVolume "41" @default.
• W4324136997 isParatext "false" @default.
• W4324136997 isRetracted "false" @default.
• W4324136997 workType "article" @default.